GLP-1 receptor agonists: The good, the bad, and the ugly-A comprehensive guide for NPs
Listen to this summary
This article aims to provide nurse practitioners (NPs) with a comprehensive understanding of glucagon-like peptide-1 receptor agonists (GLP-1RAs), focusing on their indications, benefits, risks, and prescribing considerations. The authors discuss the effectiveness of GLP-1RAs in managing diabetes and obesity, while also addressing challenges such as side effects and accessibility issues. Additionally, they highlight the emerging research on the broader therapeutic potential of GLP-1RAs, emphasizing the critical role of NPs in patient education and safe prescribing practices.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from The Nurse practitioner
View all →Apr 23, 2026 · The Nurse practitioner
Development of an advancement pathway for NPs in critical care to promote job satisfaction and retention
Apr 23, 2026 · The Nurse practitioner
Artificial intelligence for early detection of aortic stenosis: The emerging role of NPs
Apr 23, 2026 · The Nurse practitioner
Optimizing outcomes in major depressive disorder
Mar 24, 2026 · The Nurse practitioner
Integrating business skills into NP education: A competency-aligned approach
Mar 24, 2026 · The Nurse practitioner
Academic EHR integration in family NP education: Student experiences and perceived benefits
Mar 24, 2026 · The Nurse practitioner
DNP-PhD: A transformative shift
More in Nurse Practitioner
View all →May 11, 2026 · JAMA
Predictors of Long-Term Outcomes in Hypertrophic Cardiomyopathy: The NHLBI HCM Registry
May 10, 2026 · JAMA
Efficacy and Safety of Digitalis Glycosides in Heart Failure: A Meta-Analysis
May 10, 2026 · JAMA
Digoxin in Patients With Symptomatic Rheumatic Heart Disease: A Randomized Clinical Trial
May 8, 2026 · Critical care medicine
Ivermectin for Critically and Noncritically Ill Hospitalized Patients With COVID-19: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP)
May 8, 2026 · JAMA
Intravenous Tirofiban After Tenecteplase in Acute Ischemic Stroke: The INSTANT Randomized Clinical Trial
May 8, 2026 · JAMA
Intravenous Tenecteplase Prior to Endovascular Treatment for Ischemic Stroke at 4.5 to 24 Hours: The TNK-PLUS Randomized Clinical Trial
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
